CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis

Exclusion Criteria13

• Participants with ACLF grade 2 and above according to the criteria published by Moreau
• Participants with CLIF-C AD score ≥ 66, who have a high mortality similar to ACLF ≥2 participants.
• Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the West-Haven classification, unable to give consent.
• Participants with active hepatocellular carcinoma (HCC) or history of HCC that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.
• Participants with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD >2, chronic kidney disease with serum creatinine >2mg/dL or under renal replacement therapy.
• Participants with documented refractory ascites on a palliative pathway.
• Participants who are active on the transplant waiting list.
• Participants with current extra hepatic malignancies including solid tumours and hematologic disorders.
• Participants with mental incapacity, significant language barriers, or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.
• Participants with active viral infections, or yet to achieve clear response to anti-viral therapy.
• Any disorders likely to impact on study engagement, including severe frailty, severe addiction history (including opioids) with evidence of multiple recent relapses.
• Any other reason that the PI considers would make the participant unsuitable to enter CirrhoCare (e.g., participants on an end-of-life palliative care pathway).
• Participants enrolled in other interventional trials.